Alert

Ernexa Therapeutics Inc. (ERNA)

NasdaqCM: ERNA · Real-Time Price · USD

4.55

+0.11 (2.48%)

At close: Aug 12, 2026, 11:33 AM

2.48% (1D)

Bid	3.26
Market Cap	5.31M
Revenue (ttm)	n/a
Net Income (ttm)	-11.4M
Beta	2.56
EPS (ttm)	-5.19
PE Ratio (ttm)	n/a
Forward PE	-0.47
P/B (ttm)	0.77
P/S (ttm)	n/a
Earnings Date	Apr 15, 2022

Ask	5.78
Volume	6,098
Avg. Volume (20D)	546,217
Open	4.52
Previous Close	4.44
Day's Range	4.52 - 4.63
52-Week Range	3.18 - 71.50
Analyst	Strong Buy
Price Target	30 (559.34%)
Dividends	n/a
Ex-Dividend Date	n/a

About ERNA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a li...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 29, 1991

Employees 5

Stock Exchange NasdaqCM

Ticker Symbol ERNA

Website https://www.ernexatx.com

Full Company Profile

Financial Performance

In 2025, Ernexa Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 582K. Earnings were -14.08M, a decrease of -68.38%.

Financial Statements

Analyst Forecast

According to 1 analyst ratings, the average rating for ERNA stock is "Strong Buy". The 12-month stock price forecast is 30, which is upside of 559.34% from the latest price.

Stock Forecasts

Earnings Surprise

Ernexa Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -3.4 misses estimates by -0.10, with 99.73% YoY growth.

Next Earnings Release

Ernexa Therapeutics Inc. is scheduled to release its earnings on Apr 15, 2022, after market closes.
Analysts project revenue of ... Upgrade

News

3 weeks ago · InvestorsHub

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatme...

2 months ago · Zacks

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

2 months ago · 24/7 Wall St.

Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, w...

3 months ago · InvestorsHub

Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models

Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor elimination and long-term survival in ovarian cancer models when combined with...

9 months ago · Associated Press Finance

BC-Most Active Stocks

YY Group Holdings Ltd. 56,330,377 0.4678

Page 1 of 2

Ernexa Therapeutics Inc. (ERNA)